Testing effectiveness (Phase 2)Study completedNCT03852251
What this trial is testing
AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
Who this might be right for
Gastric AdenocarcinomaAdvanced Solid TumorsGastroesophageal Junction Adenocarcinoma
Akeso 338